A carregar...
Strategies, Design, and Chemistry in siRNA Delivery Systems
Emerging therapeutics that utilize RNA interference (RNAi) have the potential to treat broad classes of diseases due to their ability to reversibly silence target genes. In August 2018, the FDA approved the first siRNA therapeutic, called ONPATTRO™ (Patisiran), for the treatment of transthyretin-med...
Na minha lista:
| Publicado no: | Adv Drug Deliv Rev |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6745264/ https://ncbi.nlm.nih.gov/pubmed/31102606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.addr.2019.05.004 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|